|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-0.25/-0.37
|
Enterprise Value
659.17M
|
Balance Sheet |
Book Value Per Share
0.51
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
10.00M
|
Operating Revenue Per Share
0.06
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/10/31 19:22 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). |